> Procedures > Diagnostic Procedure > Cerebral Ventriculography

Cerebral Ventriculography

Q: What are the different types of Cerebral Ventriculography procedures?

Cerebral Ventriculography can be performed using different techniques, including pneumoventricular ventriculography, where air is injected into the ventricles, and contrast-enhanced ventriculography, where a contrast agent is used. The choice of technique depends on the specific clinical needs and the information required for diagnosis or treatment planning.

Q: What are the common applications of Cerebral Ventriculography?

Cerebral Ventriculography is primarily used to diagnose and evaluate a variety of neurological conditions, such as hydrocephalus, tumors, cysts, and other structural abnormalities within the ventricular system. It can help determine the size, shape, and position of the ventricles, as well as identify any obstructions or irregularities that may be present.

Cerebral Ventriculography is a radiographic imaging technique used to visualize the cerebral ventricles, the fluid-filled cavities within the brain.
This procedure involves the injection of a contrast agent into the ventricular system, allowing for the detailed assessment of the size, shape, and position of the ventricles.
Cerebral Ventriculography can be used to diagnose a variety of neurological conditions, such as hydrocephalus, tumors, and other structural abnormalities.
The PubCompare.ai platform provides a comprehensive, AI-powered solution for researchers to explore the latest advancements in this field, quickly identify the best protocols and products from literature, pre-prits, and patents, and optimize their research efforts.

Most cited protocols related to «Cerebral Ventriculography»

MESA Cardiovascular Event Adjudication Protocol

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008

Angina Pectoris Asymptomatic Diseases Biological Markers Blood Vessel Brain Brain Metastases Cardiovascular System Cerebral Ventriculography Cerebrovascular Accident Chest Pain Clinical Reasoning Compassion Fatigue Congenital Abnormality Coronary Artery Disease Coronary Occlusion Diagnosis Dyspnea Echocardiography Edema Exercise Tests Heart Heart Ventricle Hospitalization Infection Interviewers Left Ventricular Diastolic Dysfunction Myocardial Infarction Myocardial Ischemia Neoplasms Outpatients Patients Physical Examination Physicians Pulmonary Edema Radiography, Thoracic Traumatic Brain Injury Wounds and Injuries

CMR Imaging of Primary Prevention ICD Patients

This prospective study comprised the CMR imaging arm of the Prospective Observational Study of implantable Cardioverter Defibrillators (PROSE-ICD; NCT00733590), which enrolls patients receiving ICD therapy for primary prevention of SCD. Between November 2003 and December 2010, we approached patients with LVEF≤35% (assessed clinically by echocardiography, nuclear, or ventriculography) scheduled for clinically-indicated primary prevention ICD insertion, based on published guidelines,^{20 (link)} at the Johns Hopkins Medical Institutions. Exclusion criteria are listed in the Online Data Supplement. We enrolled 235 patients (30% of eligible patients). The reasons for non-enrollment were refusal to participate in research (78% of those non-enrolled), claustrophobia (7%) and insufficient time to schedule the scan before device implantation (15%).
We included both ischemic and nonischemic cardiomyopathy. Patients were classified as nonischemic if they had no history of myocardial infarction or revascularization and no coronary artery stenoses >50% of ≥2 major epicardial vessels or involving the left main or proximal left anterior descending artery.^{21 (link)} CMR was performed as close in time to ICD insertion as logistically possible (median 3 days). The study protocol was approved by the Johns Hopkins Hospital Institutional Review Board. All patients gave written informed consent.

Wu K.C., Gerstenblith G., Guallar E., Marine J.E., Dalal D., Cheng A., Marbán E., Lima J.A., Tomaselli G.F, & Weiss R.G. (2012). Combined Cardiac MRI and C-Reactive Protein Levels Identify a Cohort at Low Risk for Defibrillator Firings and Death. Circulation. Cardiovascular Imaging, 5(2), 178-186.

Publication 2012

Arteries Blood Vessel Cardiomyopathies Cerebral Ventriculography Claustrophobia Coronary Stenosis Dietary Supplements Echocardiography Ethics Committees, Research Implantable Defibrillator Medical Devices Myocardial Infarction Ovum Implantation Patients Primary Prevention Radionuclide Imaging

Warfarin Therapy for Heart Failure

Eligible patients were 18 years of age or older and had normal sinus rhythm, no contraindication to warfarin therapy, and an LVEF of 35% or less as assessed by quantitative echocardiography (or a wall-motion index of ≤1.2) or as assessed by radionuclide or contrast ventriculography within 3 months before randomization. Patients who had a clear indication for warfarin or aspirin were not eligible. Patients in any New York Heart Association (NYHA) functional class were eligible, but patients in NYHA class I could account for no more than 20% of the total number of patients undergoing randomization. Additional eligibility criteria were a modified Rankin score of 4 or less (on a scale of 0 to 6, with higher scores indicating more severe disability), and planned treatment with a beta-blocker, an angiotensin-converting–enzyme (ACE) inhibitor (or, if the side-effect profile with ACE inhibitors was unacceptable, with an angiotensin-receptor blocker), or hydralazine and nitrates. Patients were ineligible if they had a condition that conferred a high risk of cardiac embolism, such as atrial fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or pedunculated thrombus.

Homma S., Thompson J.L., Pullicino P.M., Levin B., Freudenberger R.S., Teerlink J.R., Ammon S.E., Graham S., Sacco R.L., Mann D.L., Mohr J.P., Massie B.M., Labovitz A.J., Anker S.D., Lok D.J., Ponikowski P., Estol C.J., Lip G.Y., Di Tullio M.R., Sanford A.R., Mejia V., Gabriel A.P., del Valle M.L, & Buchsbaum R. (2012). Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. The New England journal of medicine, 366(20), 1859-1869.

Publication 2012

Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Aspirin Atrial Fibrillation Cerebral Ventriculography Disabled Persons Echocardiography Eligibility Determination Embolism Endocarditis Heart Heart Valves Hydralazine Nitrates Patients Radioisotopes Sinuses, Nasal Thrombus Warfarin

Diagnosing Congestive Heart Failure

Median follow-up time was 4.0 years (interquartile range, 3.1-4.2 years), which resulted in 25 107 person-years of observation. A telephone interviewer contacted each participant every 6 to 9 months to inquire about all interim hospital admissions, cardiovascular outpatient diagnoses, and deaths. Two physicians reviewed each record for independent endpoint classification and assignment of event dates.
The endpoint for this study was symptomatic CHF. End point criteria were (a) CHF diagnosed by a physician and patient receiving medical treatment for CHF; (b) pulmonary edema/congestion seen on a chest radiograph; and (c) dilated ventricle or poor LV systolic function by echocardiography or ventriculography, or evidence of LV diastolic dysfunction by echocardiography. Participants who met only criterion a were considered to meet a “soft” criterion, and participants who met criteria b and c in addition to a physician diagnosis were classified as meeting “hard” criteria for CHF. For this analysis, participants who met either soft or hard criteria were considered as having incident CHF. An MI was diagnosed based on standard criteria consisting of combinations of symptoms, ECG findings, and cardiac biomarker levels.24 (link)

Bahrami H., Kronmal R., Bluemke D.A., Olson J., Shea S., Liu K., Burke G.L, & Lima J.A. (2008). Differences in the Incidence of Congestive Heart Failure by Ethnicity: The Multi-Ethnic Study of Atherosclerosis. Archives of internal medicine, 168(19), 2138-2145.

Publication 2008

Biological Markers Cardiovascular System Cerebral Ventriculography Echocardiography Heart Heart Ventricle Interviewers Left Ventricular Diastolic Dysfunction Outpatients Patients Physicians Pulmonary Edema Radiography, Thoracic Systole Vision

Hospitalized Heart Failure Adjudication in WHI

Incident hospitalized HF was ascertained yearly in WHI by medical record abstraction of self-report hospitalizations and classified by trained adjudicators using the standardized methodology as previously described.^{18 (link)} Hospitalized HF requiring and/or occurring during hospitalization required physician diagnosis of new-onset or worsened congestive HF on the reported hospital admission and 1 or more of the following 4 criteria: HF diagnosed by physician and receiving medical treatment for HF, symptoms plus documentation in the current medical record of a history of an imaging procedure showing impaired left ventricular (LV) systolic or diastolic LV function, pulmonary edema/congestion on chest x-ray on the current admission, dilated ventricle(s) or “poor” LV or right ventricular (RV) function by echocardiography, radionuclide ventriculography, or other contrast ventriculography, or evidence of LV diastolic dysfunction. This method was found to have an excellent 79% agreement rate (kappa) comparing central adjudicated HF to local adjudication.^{18 (link)}Interim CHD was defined by adjudicated hospitalization for myocardial infarction, PTCA, CABG, or angina after baseline and prior to the HF hospitalization.^{18 (link)}

Eaton C.B., Abdulbaki A.M., Margolis K.L., Manson J.E., Limacher M., Klein L., Allison M.A., Robinson J.G., Curb J.D., Martin L.A., Liu S, & Howard B.V. (2012). Racial and Ethnic Differences in Incident Hospitalized Heart Failure in Post Menopausal Women: The Women’s Health Initiative. Circulation, 126(6), 688-696.

Publication 2012

Angina Pectoris Cerebral Ventriculography Coronary Artery Bypass Surgery Diastole Echocardiography Heart Ventricle Hospitalization Left Ventricles Left Ventricular Diastolic Dysfunction Left Ventricular Function Medical Imaging Myocardial Infarction Percutaneous Transluminal Coronary Angioplasty Physicians Pulmonary Edema Radiography, Thoracic Radionuclide Ventriculography Systole Ventricular Function, Right

Most recents protocols related to «Cerebral Ventriculography»

Retrospective Analysis of CAD Patients

A retrospective cohort analysis was used for this study. Ninety-seven patients diagnosed with CAD at the Department of Cardiovascular Medicine in the Affiliated Hospital of Xuzhou Medical University from September 2021 and January 2022 were selected. LVEDP ≥ 16 mmHg (1 mmHg = 0.133 kPa) was defined as increased LV filling pressure [7 (link), 8 (link)]. Based on LVEDP, patients were divided into the HFpEF group (LVEDP ≥ 16 mmHg, 47 cases) and the normal LV diastolic function group (LVEDP < 16 mmHg, 50 cases). The Medical Ethics Committee approved the study of the Affiliated Hospital of Xuzhou Medical University (Number: XYFY2021-KL164-01).
Inclusion criteria: (1) All patients with suspected or known coronary artery disease who have completed echocardiography, planar MUGA and cardiac catheterization 1–3 days after admission and whose diagnosis of CAD was confirmed by coronary arteriography with a subepicardial coronary artery diameter stenosis more than 50% [9 (link)]; (2) sinus rhythm; (3) hemodynamic stability; (4) LVEF ≥ 50% (based on left ventriculography findings) .
Exclusion criteria: pulmonary heart disease (10), congenital heart disease (1), rheumatic heart disease (0), cardiomyopathy and pericardial disease (2), hyperthyroidism (2), arrhythmias (5), severe anemia (0), severe hepatic and renal dysfunction (1), LVESV′ < 20 mL measured by planar MUGA (3) (because assessment of LV volume and function is less accurate in very small volume patients [6 (link), 10 (link)]).

Liu Q., Zhou S., Wu Q., Zuo R., Xiao S., Wang X., Liu A., Liu J., Zhu H, & Pan D. (2023). Diagnostic value of parameters derived from planar MUGA for detecting HFpEF in coronary artery disease patients. BMC Cardiovascular Disorders, 23, 35.

Publication 2023

Anemia Cardiac Arrhythmia Cardiomyopathies Cardiovascular Agents Catheterizations, Cardiac Cerebral Ventriculography Congenital Heart Defects Coronary Angiography Coronary Artery Disease Coronary Stenosis Cor Pulmonale Diagnosis Diastole Echocardiography Ethics Committees Gated Blood-Pool Imaging Hemodynamics Hyperthyroidism Kidney Failure Patients Pericardium Pressure Rheumatic Heart Disease Sinuses, Nasal

Diagnosis of Cardiac Ischemia via Catheterization

Heart catheterization was performed only in patients with a history of typical chest pains during exercise or at rest, signs of ischemia in ECG and/or dynamic changes in cardiac marker levels. In cases, when a ventriculography was performed, LVEDP was measured invasively with a pigtail catheter placed in the left ventricle.

Hautmann M., Zacher M., Fuchs S., Pérez C.M., Ahmidou A., Kerber S, & Barth S. (2023). Left atrial appendage thrombus formation, potential of resolution and association with prognosis in a large real-world cohort. Scientific Reports, 13, 889.

Publication 2023

Catheterizations, Cardiac Catheters Cerebral Ventriculography Chest Pain Heart Ischemia Left Ventricles Patients

Left Ventricular Reconstruction in Patients with Myocardial Infarction

Figure 1 shows the flow chart of our study. Among 1398 patients undergoing left ventricular reconstruction (LVR), there were 10 patients with prior myocardial infarction in the absence of obstructive coronary artery on preoperative angiogram. These 10 patients constituted the target population in this study. The operative indication for LVR was the presence of both of the following criteria: (1) there was clear evidence of aneurysmal and akinetic left ventricle according to echocardiography, left ventriculography, or magnetic resonance imaging. (2) patients presented symptoms of heart failure, refractory angina, thromboembolism, a concomitant structural cardiac disease requiring surgery or ventricular arrhythmias which were refractory to medical treatment, implantable cardioverter defibrillator, and endocardial ablation [10 ].
Fig. 1

Flow chart of the study

Song Y., Xu F, & Feng W. (2023). Surgical treatment of left ventricular aneurysm in patients with prior myocardial infarction in the absence of obstructive coronary artery disease (MINOCA): a cohort study. Journal of Cardiothoracic Surgery, 18, 304.

Publication 2023

Aneurysm Angina Pectoris Angiography Artery, Coronary Cardiac Arrhythmia Cerebral Ventriculography concomitant disease Echocardiography Endocardium Heart Heart Diseases Heart Failure Heart Ventricle Implantable Defibrillator Left Ventricles Myocardial Infarction Operative Surgical Procedures Patients Reconstructive Surgical Procedures Surgical Procedure, Cardiac Target Population Thromboembolism

Serum Reactivity and Incident Heart Failure

We also investigated associations between serum reactivity to citrullinated protein/peptide antigens and incident heart failure. These events were adjudicated by a committee in MESA, and included both definite and probable heart failure, defined by heart failure symptoms, and by physician diagnosis with medical treatment. Specifically, definite and probable heart failure required clinical symptoms, e.g., shortness of breath, and signs e.g., edema since asymptomatic disease was not an endpoint. Probable heart failure required a physician diagnosis and medical treatment for heart failure. Definite heart failure required pulmonary edema/congestion on chest x-ray and/or dilated ventricle or poor LV function by echocardiography or ventriculography, or evidence of LV diastolic dysfunction [30 (link), 31 (link)].

Hughes-Austin J.M., Katz R., Majka D.S., Criqui M.H., Robinson W.H., Firestein G.S., Hundley W.G, & Ix J.H. (2023). Serum reactivity to citrullinated protein/peptide antigens and left ventricular structure and function in the Multi-Ethnic Study of Atherosclerosis (MESA). PLOS ONE, 18(10), e0291967.

Publication 2023

Antigens Asymptomatic Diseases Cerebral Ventriculography Congestive Heart Failure Diagnosis Dyspnea Echocardiography Edema Heart Heart Ventricle Left Ventricular Diastolic Dysfunction Peptides Physicians Proteins Pulmonary Edema Radiography, Thoracic Serum Sickness

Transesophageal Echocardiography-Guided Transcatheter Closure of Ventricular Septal Defects

The procedure was performed under general anesthesia using transesophageal echocardiography (TEE) control. A left ventriculography was performed to assess the anatomy of the defect. The choice of device was always determined according to the TEE dimension of the defect on the right ventricular side with possible modifications related to the dimension on the left ventricular side [5 (link)]. Device implantation was performed using either a retrograde or antegrade approach. In the retrograde approach, no complete arteriovenous loop was required. Regardless of the approach used, TEE was always used to check after deployment but before release, the device position, the amount of residual shunting, and the presence of aortic or tricuspid valve regurgitation. All patients had 24-h continuous/telemetry monitoring after implantation. The patients were discharged from hospital on the following day, after TTE and electrocardiogram (ECG) control, most often without any treatment or sometimes, at the beginning of our experience, under aspirin (3–5 mg/kg once daily for 6 months). In the case of a residual shunt, hemolysis was determined using blood and urine analyses. Endocarditis prophylaxis was recommended for the first 6 months. Routine outpatient follow-up visits were planned at 1 month, 3 to 6 months, and 12 months after implantation, and thereafter annually including TTE and ECG monitoring. On TTE, the residual shunt was graded according to the color jet width and defined as small (1–2 mm), moderate (2–4 mm), or large (>4 mm) [2 (link),5 (link)].

Godart F., Baudelet J.B., Delarue A., Polge A.S., Domanski O., Bichali S, & Houeijeh A. (2023). Transcatheter Closure of Perimembranous Ventricular Septal Defects Including Multifenestrated and Gerbode-Type Defects Using the Lifetech Konar Device. Journal of Clinical Medicine, 12(19), 6370.

Publication 2023

Aorta Aspirin BLOOD Cerebral Ventriculography Echocardiography, Transesophageal Electrocardiogram Endocarditis General Anesthesia Hemolysis Left Ventricles Medical Devices Outpatients Ovum Implantation Patients Telemetry Tricuspid Valve Insufficiency Urinalysis Ventricles, Right

Top products related to «Cerebral Ventriculography»

Digital cardiac imaging software by Philips

The Digital cardiac imaging software is a medical imaging application developed by Philips. It is designed to assist healthcare professionals in the analysis and interpretation of cardiac imaging data, such as echocardiograms, cardiac MRI, and CT scans. The software provides tools for visualization, measurement, and quantification of cardiac structures and functions.

Aia cl2400 by Tosoh

Sourced in Japan

The AIA-CL2400 is an automated immunoassay analyzer designed for clinical diagnostic laboratories. It is capable of performing a variety of immunoassay tests, including those for hormones, tumor markers, and infectious disease markers. The system is equipped with advanced features to ensure efficient and reliable performance, but a detailed description of its specific functionality or intended use is not available.

Epiq 7 by Philips

Sourced in United States, Netherlands, Germany, Norway, United Kingdom

The EPIQ 7 is a high-performance ultrasound imaging system designed for a wide range of clinical applications. It features advanced imaging technologies and a user-friendly interface to provide clear and detailed images for diagnosis and treatment planning.

Spc 454d by Millar

Sourced in United States

The SPC-454D is a laboratory instrument designed for spectrophotometric analysis. It is capable of measuring the absorbance or transmittance of light through a sample across a range of wavelengths, providing quantitative data about the composition or concentration of the sample.

Cobas 8000 by Roche

Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden

The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.

Oec 9800 plus by GE Healthcare

Sourced in United States

The OEC 9800 Plus is a mobile C-arm imaging system designed for use in various medical procedures. It provides high-quality real-time imaging capabilities to assist healthcare professionals during surgical and diagnostic interventions.

Centaur xpt by Siemens

Sourced in Germany

The Centaur XPT is a laboratory equipment product from Siemens. It is a clinical chemistry analyzer designed for the automated analysis of various bodily samples, such as blood, urine, or other fluids. The Centaur XPT is capable of performing a wide range of diagnostic tests, including biochemical, immunoassay, and drug testing procedures.

Vitros troponin 1 assay by Ortho Clinical Diagnostics

Sourced in United States

The VITROS® troponin I assay is a diagnostic tool used to measure the concentration of troponin I in human blood samples. Troponin I is a specific protein found in the heart muscle, and its presence in the blood can indicate damage to the heart, such as that caused by a heart attack. The VITROS® assay provides a quantitative measurement of troponin I levels, which can be used by healthcare professionals to aid in the diagnosis and management of various heart-related conditions.

Human galectin 1 quantikine elisa kit dgal10 by R&D Systems

Sourced in United States

The Human Galectin-1 Quantikine ELISA Kit DGAL10 is a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) designed for the measurement of human galectin-1 levels in cell culture supernates, cell lysates, serum, and plasma.

6 f pigtail catheter by Cordis

Sourced in Ireland

The 6-F pigtail catheter is a medical device used for various diagnostic and interventional procedures. It is designed with a pigtail-shaped distal end, which allows for secure placement within the body. The catheter has a 6-French diameter, which refers to its size. The core function of the 6-F pigtail catheter is to provide a conduit for the introduction and manipulation of other medical instruments or contrast media within the body.

What are the different types of Cerebral Ventriculography procedures?

What are the common applications of Cerebral Ventriculography?

What are some of the challenges or limitations associated with Cerebral Ventriculography?

One of the main challenges with Cerebral Ventriculography is the risk of complications, such as infection, bleeding, or even seizures, due to the invasive nature of the procedure. Additionally, the interpretation of the images can be subjective and require expertise, and the procedure may not be suitable for all patients, particularly those with certain medical conditions or contraindications.

How can PubCompare.ai help with Cerebral Ventriculography research?

PubCompare.ai's AI-powered platform can assist researchers in several ways when it comes to Cerebral Ventriculography. The platform allows you to efficiently screen protocol literature, leveraging AI to pinopint critical insights that can help you identify the most effective protocols related to Cerebral Ventriculography for your specific research goals. The platform's analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accuracy in your work.

More about "Cerebral Ventriculography"

Cerebral Ventriculography is a radiographic imaging technique used to visualize the fluid-filled cavities within the brain, known as the cerebral ventricles.
This procedure involves the injection of a contrast agent into the ventricular system, allowing for a detailed assessment of the size, shape, and position of the ventricles.
Cerebral Ventriculography can be used to diagnose a variety of neurological conditions, such as hydrocephalus, tumors, and other structural abnormalities.
The PubCompare.ai platform provides a comprehensive, AI-powered solution for researchers to explore the latest advancements in this field.
Researchers can quickly identify the best protocols and products from literature, pre-prints, and patents using the platform's advanced search and analysis tools.
This can help optimize research efforts and stay up-to-date with the latest developments in cerebral ventriculography.
In addition to the cerebral ventriculography technique, researchers may also be interested in exploring related imaging technologies, such as digital cardiac imaging software, AIA-CL2400, EPIQ 7, SPC-454D, Cobas 8000, OEC 9800 Plus, and Centaur XPT.
These tools can provide valuable insights and support for researchers working in the field of neurovascular imaging and diagnostics.
Furthermore, researchers may also be interested in exploring related biomarkers and assays, such as the VITROS® troponin I assay and the Human Galectin-1 Quantikine ELISA Kit DGAL10.
These tools can provide additional data and insights to support the diagnosis and monitoring of neurological conditions.
Overall, the PubCompare.ai platform offers a powerful and comprehensive solution for researchers working in the field of cerebral ventriculography and related imaging technologies.
By leveraging the platform's advanced search and analysis capabilities, researchers can optimize their research efforts and stay at the forefront of the latest advancements in this important field of study.